Navigation Links
Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
Date:9/16/2010

HAYWARD, Calif., Sept. 16 /PRNewswire/ -- The board of directors of Intarcia Therapeutics, Inc. ("Intarcia," the "Company") today announced the appointment of Kurt Graves as executive chairman of the board. In the newly created position, Mr. Graves will provide strategic leadership to the board and work closely with management as the Company seeks to advance into late stage development with its potential blockbuster asset, ITCA 650 (DUROS® continuous delivery of exenatide). His appointment follows a focused search for a highly regarded pharmaceutical executive with a track record of success based on keen market place insights, optimal commercial positioning, development and regulatory expertise, and astute business development and M&A initiatives.

(Logo:  http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

"I'm excited about joining Intarcia's board based on the Company's potential to make a dramatic difference in patient outcomes in one of the largest and most important disease areas in the industry – type 2 diabetes. We have two breakthrough formulation and drug delivery platforms that have translated into a highly differentiated GLP-1 asset poised to enter into phase 3 trials early next year. Final phase 2 data will be presented at EASD next week and it is now a matter of elevating our sights to the level of the opportunities before us to capture the full upside for patients and investors," said Kurt Graves, newly appointed executive chairman of the board. He added, "I am impressed with the board's and the management team's commitment to win and maximize value going forward."

Intarcia's innovations center on its capability to stabilize proteins and peptides at above body temperatures and its ability to deliver drugs in a consistent, steady state manner via the DUROS delivery technology platform.  The DUROS device is a subcutaneous, matchstick-size osmotic mini-pump with therapeutic applications currently under development in several different medical conditions and disease categories, including type 2 diabetes, and weight regulation to help control obesity.  Through these efforts, the Company hopes to develop and commercialize therapies that ensure the best treatment outcome for patients by enhancing the efficacy and tolerability of medicines, eliminating the need for frequent injections, and transforming patient adherence by delivering up to a full year's worth of therapy in just one device.

"Kurt has the vision it takes to identify commercial opportunity in the face of very established competitive categories and break through the clutter with strategic precision," said K. Alice Leung, president and chief executive officer. "It is that type of vision and guidance that will help us fully realize our mission and our business aspirations, including moving our lead diabetes program, ITCA 650, into Phase 3 clinical trials and pre-commercialization."

Regarded by many as a one of the pharmaceutical industry's most successful commercial strategists, Mr. Graves most recently served as executive vice president, head of corporate and strategic development and chief commercial officer at Vertex Pharmaceuticals Inc. During his tenure, the market cap increased from $2 billion to nearly $8 billion based on advancing several blockbuster potential drugs and completing several strategic transactions. Prior to joining Vertex, Mr. Graves held various senior leadership positions at Novartis Pharmaceuticals since 1999 including US general manager and head of Commercial Operations and then global head of the General Medicines and chief marketing officer for the Pharmaceuticals Division, during a period of record growth and multiple blockbuster launches. Prior to joining Novartis, Mr. Graves held various commercial and general management positions since 1990 at Merck and Astra/Merck Pharmaceuticals including US GI Business Unit Head, another multi-billion dollar business with responsibility for Prilosec®, Nexium® and the Prilosec OTC alliance with P&G.

In addition to his new post as executive chairman of Intarcia Therapeutics, Mr. Graves serves as a director at Pulmatrix Pharmaceuticals, Alevium Pharmaceuticals, and Entra Therapeutics.  Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.

About IntarciaIntarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing a clinical stage development program for type 2 diabetes and has other programs for weight regulation to control obesity.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation licensed to Intarcia Therapeutics, Inc. in certain fields. MEDIA CONTACT:Intarcia Therapeutics:Wholepoint Communications:James Ahlers

Jody LoMenzo510.782.7800

804.272.1031jody.lomenzo@wholepoint.com
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Echo Therapeutics to Present at Prestigious Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference
3. Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
4. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
5. Halozyme Therapeutics Announces Public Offering of Common Stock
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
10. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
(Date:8/31/2017)... NEW YORK , Aug. 31, 2017 ... the industry,s must-read guide to the latest innovations happening ... the first industry publication to focus on providing a ... advancements. Ultimately, the issue covers the most innovative companies, ... year. "Everyone in ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Doctors on Liens has added the medical group ... professionals working on a personal injury lien basis. Founded by Dr. Wayne Cheng, MD ... doctors’ vast experience with orthopedic injuries to patients in the Inland Empire. , Bones ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The ... unveiled a redesigned website. The new site – still located at http://www.garlandco.com ... contractors and other industry users that Garland serves. , After an ambitious phase ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) products were selected ... different categories. Nopavera Plus was named to the short list in the ... West 2017 during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay ...
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take on one ... better one’s life through God. “The Trials I Face to Receive God’s Grace” is ... found a love for writing. Green feels that expressing his feelings through prayer will ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the inspirational ... to God. “Psalms of Humidity” is the creation of published author, David Waldrop, an ... life are the very same things that have shaped him into the man that ...
Breaking Medicine News(10 mins):